Hualan Biological Engineering (SHE:002007) affiliate Hualan Ankang Biological received marketing authorization for its trastuzumab for injection, according to a Wednesday filing with the Shenzhen bourse.
The drug is indicated for HER2-positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer, the filing said.